Praxis Precision Medicines UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Well, thank you everyone for joining us for this inaugural UBS Global Biopharma Conference. My name is Joon Lee, one of the biotech analysts here. For this session, we have Marcio Souza, CEO of Praxis. Marcio, thank you so much for joining us for the fireside chat. You have arguably the most consequential biotech catalyst, the January 29 PDUFA for ulixacaltamide, and you have two more before that. I mean, the bases are loaded. To prepare for all this, you hosted an investor event detailing how you will be the preeminent neurology franchise, even exceeding that of some of the pharmas. Praxis is a relatively new stock coverage for UBS, and for the audience who may be new to the story, just tell us a little bit about Praxis, where you are, and why it matters for the investors.
I think where we are is two NDAs in front of us, 21 programs, and I know the audience is going to want to talk a lot about Ulixa. Incredibly excited about that, as you can imagine, with the NDA approval coming in, and I'm even saying approval because I think that's really the stage we're in right now in January. There is not a lot of times in life that you come with a drug that 9 million Americans, many, many million outside of the U.S. suffer from, and there's really nothing Yeah from them.
For more than I would like to talk about the entire portfolio, and I'll be happy to talk about that, and I'm sure Tim and Megan and John, who are here with me, could do that as well. With incredible respect to everything else we're doing and to the needs of these patients, when you think about the scale of the company, you talked about the event we had last Thursday, which is hard to believe that was two days ago or working days ago. The scale of Ulixa is disproportional to anything else. Once again, I mean no disrespect to AbbVie and others that were in our list last week as companies that did incredibly well, but the giants always stand on the shoulders of when we think about CNS.
As we're seeing more and more CNS companies moving into going back to these massive markets, that we're happy to be one of the most advanced ones. I think we are thrilled today, of course. There were times that we're having conversations like this that we were like, "Oh, do people even understand what essential tremor is? Do people even understand what SCN2A is?" You name it. We're no longer there, right? We're at the point that I think you and your colleagues did a lot of work to understand these markets. Ironically, I may say, a lot of people are coming back to us and saying, "Well, when you put $10 billion last year as the potential, no one really believed this." Now we're getting questions as why we were conservative with that, which I could never imagine I would get, to be honest.
But it doesn't stop there. You might recall probably one of our first conversations in our past lives here in terms of what we are doing today. You talked about how big of an activity this can be, as a company. I said, "That's not what we are focusing on at that point in time." To be honest, today, I think we're focusing on and to look into areas of biology and medicine that can make a real difference, and that have a real value on the other side. But it has to first make a difference, and then the value will follow. We announced last week that we're doing three extension studies for ulixacaltamide hydrochloride, one in restless legs syndrome, one in Parkinson's disease, and one in autism spectrum disorder. They're all starting pretty soon.
I think Parkinson's is the obvious, if I may, and for all of you, not obvious- Is it Parkinson's disease or parkinsonism?
Yeah, it's Parkinson's tremor- Okay the way we're looking into this, which is a very, very large number of Yeah Parkinson's patients.
It's actually normally how we think about Parkinson's first, right? Then it progress. There was this impression that, "Oh, we know it's actually that is not that big of a deal." And the more work we've done, it's actually a huge deal for these patients. It's one of the most debilitating complex disease, but an expansion there. Restless legs, I think it goes without saying, I'm sure a bunch of people in this audience has it. It's such a prevalent condition. Great drugs are currently approved, but unfortunately, they lead to very quick, not only loss of effect, but worsening of effect while we stay on drug with the current treatment, so augmentation. It's probably the riskiest clinically of problems that we decided to go in, but it's a classical dislocated risk-reward perspective. And then maybe the last obvious that we discussed last week is ASC.
There is really tons of very good work done pre-clinically by independent researchers on that. It makes scientific sense, and soon enough, it's going to make clinical sense to all of you once we start. I can keep going on and on because there are 21 of those, but maybe you can talk about Yeah.
Let's do this very methodically. First things first. You had a late cycle meeting with the FDA.
from the meeting gives you confidence on the approval? Because it needs to be approved first.
Yeah. What's the- Everything about the meeting gives us confidence, and I don't say that lightly.
I think everyone's like, "Oh, I cannot speak for the FDA," and I cannot speak for the FDA, so it goes without saying that that's not what I'm trying to do here. But we all done this for a bit, a minute or two, and there are elements, and I would say the three elements, in my view, that are important in meetings like this is, one, is leadership engagements on the agency sides, how much they understand the application, how willing they are to engage in these conversations. And while we had that from the get-go, from the very beginning, I think it was incredibly strong on this meeting. I think the second has to be the formal communication, right?
It's whether or not there are some things significant that they're still looking into, there are significant questions, and that goes with the tone of the meeting as well. And without going into absolute details, because we didn't really disclose these details, what I can say is that it felt a lot more like a label discussion than a late-cycle discussion. And, of course, that is incredibly important for us. This was not the least controversial application in history of application, right? We all had many debates about aspects of applications that people not even know exists. But it was always very clear, and I'm going to just remind everyone, this is not a change in tone. From the pre-NDA meeting, what we talked about was engagement, understanding of the program, understanding of the unmet needs, certainty of the data.
We just so happened that 10 months in the future from that day, at that point, and a little bit more now, we are in this position that the certainty of getting approved is incredibly high.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
